MichaelEMingMD
Dermatology • Philadelphia, PADermatopathology
Associate Professor, Dermatology, Perelman School of Medicine
Dr. Ming is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3400 Spruce Street
2 Rhoads Pavilion
Philadelphia, PA 19104Phone+1 215-662-2737Fax+1 215-349-8339- Is this information wrong?
Education & Training
University of California (San Francisco)Fellowship, Dermatopathology, 1997 - 1999
Massachusetts General Hospital/Beth Israel Deaconess Medical Center/Brigham and Women's HospResidency, Dermatology, 1994 - 1997- Massachusetts General HospitalInternship, Internal Medicine, 1993 - 1994
Harvard Medical SchoolClass of 1993
Certifications & Licensure
CA State Medical License 1997 - Present
PA State Medical License 2000 - 2024- American Board of Dermatology Dermatology
- American Board of Dermatology Dermatopathology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Fellow (FAAD) American Academy of Dermatology
Clinical Trials
- Tailored Intervention for Melanoma Patient's Families Start of enrollment: 2005 Aug 01
Publications & Presentations
PubMed
- Pathologic characteristics and clinical outcomes of primary dermal melanoma.Gabriella N Tortorello, Eric H Li, Cimarron E Sharon, Neha Shafique, Emily Y Chu, Michael E Ming, Giorgos C Karakousis> ;Journal of the American Academy of Dermatology. 2024 Feb 23
- 5 citationsEarly Detection and Prognostic Assessment of Cutaneous Melanoma: Consensus on Optimal Practice and the Role of Gene Expression Profile Testing.Mohammed Kashani-Sabet, Sancy A Leachman, Jennifer A Stein, Jack L Arbiser, Elizabeth G Berry, Julide T Celebi, Clara Curiel-Lewandrowski, Laura K Ferris, Jane M Grant...> ;JAMA Dermatology. 2023 May 1
- 1 citationsAssociation Between Metastatic Melanoma Response to Checkpoint Inhibitor Therapy and Tumor-Infiltrating Lymphocyte Classification on Primary Cutaneous Melanoma Biopsies.Michael R Stephens, Oyinade Aderbigbe, Wei Xu, Giorgos C Karakousis, Michael E Ming, Emily Y Chu> ;JAMA Dermatology. 2023 Feb 1
- Join now to see all
Journal Articles
- Risk of Subsequent Cutaneous Melanoma in Moderately Dysplastic Nevi Excisionally Biopsied but with Positive Histologic MarginsDouglas Grossman, Vijay Balakrishnan, Laura K Ferris, Geoffrey Lim, Suephy C Chen, Meera Brahmbhatt, Susan M Swetter, Emily Y Chu, Nathaniel Fleming, Caroline C Kim, M..., JAMA
- Timing of Onset of Adverse Cutaneous Reactions Associated with Programmed Cell Death Protein 1 Inhibitor TherapyTara C Mitchell, Michael E Ming, Leo L Wang, Suzanne McGettigan, Emily Y Chu, Lynn Schuchter, JAMA
Press Mentions
Guidance on the Clinical Understanding and Use of Long‐Acting Injectable Antipsychotics in Schizophrenia: Hong Kong Consensus StatementsFebruary 8th, 2021
Cancer Patients May Experience Delayed Skin Effects of Anti-PD-1 TherapyJuly 18th, 2018
Management Strategies of Academic Pigmented Lesion Clinic Directors in the United StatesJanuary 4th, 2018- Join now to see all
Professional Memberships
- Fellow
Hospital Affiliations
Hospital of the University of PennsylvaniaPhiladelphia, Pennsylvania- Penn Presbyterian Medical CenterPhiladelphia, Pennsylvania
Pennsylvania HospitalPhiladelphia, Pennsylvania
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
